| ²é¿´: 1375 | »Ø¸´: 2 | |||
sophieyjingÒø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
¼±ÇóFDAÉúÎïÀàËÆÒ©·¨¹æµÄÖÐÎÄÒëÎÄ~лл·ÖÏí~
|
|
ÇóÒÔÏÂFDAÉúÎïÀàËÆÒ©×¢²á·¨¹æÖÐÎÄÒëÎÄ£¬Ð»Ð»·ÖÏí~ÌṩÈÎÒâһƪ¼´¿ÉÁìÈ¡Éͽð~ Sections 7001-7003 (Biologics Price Competition and Innovation Act of 2009) of the Patient Protection and Affordable Care Act (Public Law No. 111-148) Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product-Draft Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Biosimilars Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Biosimilars Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009Draft Guidance |
» ²ÂÄãϲ»¶
321Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
08¿ªÍ·275Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
329Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
294·Ö080500²ÄÁÏ¿ÆÑ§Ó빤³ÌÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
¸´ÊÔµ÷¼Á£¬Ò»Ö¾Ô¸ÄÏÅ©083200ʳƷ¿ÆÑ§Ó빤³Ì
ÒѾÓÐ3È˻ظ´
085701»·¾³¹¤³Ì£¬267Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0703»¯Ñ§Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
07»¯Ñ§280·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
081200-11408-276ѧ˶Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
sophieyjing
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 157.7
- ºì»¨: 1
- Ìû×Ó: 60
- ÔÚÏß: 18.2Сʱ
- ³æºÅ: 1610730
- ×¢²á: 2012-02-10
- ÐÔ±ð: MM
- רҵ: ѪÐÍÓëÊäѪ
2Â¥2016-10-28 08:55:13
|
3Â¥2017-08-20 11:18:31













»Ø¸´´ËÂ¥